Research Update

RNS Number:4080D
Henderson Morley PLC
28 September 2004




                                                               28 SEPTEMBER 2004

                              HENDERSON MORLEY PLC
                                      (AIM)

                        Business: Drug Discovery Company

                                RESEARCH UPDATE


The Board of Henderson Morley plc ("Henderson Morley" or "the Company")
announces an update on recent research being carried out on its platform
technology, Ionic Contra Viral Therapy ("ICVT").

Background

For the component drugs used in ICVT to be anti-virally effective, they must be
delivered to the site of virus infection. In *HPV infection, this usually means
delivering the drug to the deepest layer of the skin (the dermis), and to keep
the drugs at this site for prolonged periods of time.

To achieve this, several important technical hurdles have to be overcome.
Firstly the drugs must be formulated to be present and stable in therapeutically
appropriate concentrations. Secondly, the drug must be released easily from the
formulation (otherwise it simply stays there), and thirdly once released from
the formulation, the drug must permeate through the desired tissues, in this
case the skin. Finally the formulation must be safe and cosmetically acceptable.

Developments

The Scientific Team has been working with the Welsh National School of Pharmacy,
who are recognised leaders in the field of transdermal drug delivery, and they
have now produced a gel formulation that fulfils all of these criteria. The ICVT
drugs are stable and present in high concentrations, are released easily so as
to be available for anti-viral action, and they pass readily through the skin.

In named patient studies, it has been possible to confirm the clinical
usefulness of this formulation. In patients treated, no adverse effects were
detected, and patient satisfaction was high and warts were treated successfully.

In an effort to further improve patient compliance and speed of efficacy,
additional formulation work has been undertaken, working closely with experts in
Bio-adhesives from the Medicines Research Unit of Aston University Department of
Pharmaceutics. This has yielded a new "drug-in-glue" self adhesive dressing to
be applied to skin and plantar warts. This dressing is subject to patent
application, and, significantly, fulfils all of the important criteria
highlighted above.

These initial named patient studies have demonstrated that this latest
formulation achieves the goals of development, i.e. a rapidly active and highly
convenient form of treatment. The Company will continue to work with physicians
who are conducting named patient studies to provide additional data.
Photographic evidence of the studies can be seen in the News and Events section
on the Company's website at www.henderson-morley.com




                                    --ENDS--

Enquiries:

HENDERSON MORLEY PLC                                          Tel: 0121 442 4600
Andrew Knight, Chairman

BREWIN DOLPHIN SECURITIES LTD                                 Tel: 0113 241 0126
Neil Baldwin

BISHOPSGATE COMMUNICATIONS LTD                                Tel: 020 7430 1600
Maxine Barnes                                               Mobile: 07860 489571
Dominic Barretto

* About Human Papilloma Virus (HPV) infections
HPV is the name given to a group of more than 80 different strains of virus
associated with a variety of epidermal warts and skin lesions, some of which are
associated with cancer. Low risk sub types (type 6 and 11) are associated with
genital warts, but high risk subtypes (type 16 and 18) cause cancer of the
cervix and anus, and also cause dysplasias of anogenital tissues.




                      This information is provided by RNS
            The company news service from the London Stock Exchange

END
RESBVLFLZKBBBBB
Henderson Mrly. (LSE:HML)
過去株価チャート
から 6 2024 まで 7 2024